Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report
Open Access
- 13 February 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (2), e20
- https://doi.org/10.1136/annrheumdis-2020-216983
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Emergent high fatality lung disease in systemic juvenile arthritisAnnals Of The Rheumatic Diseases, 2019
- Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk FactorsArthritis & Rheumatology, 2019
- Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosisBlood, 2019
- AB0518 - JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS RELATED PANCREATITIS: AN UNCOMMON MANIFESTATION OF A COMMON DISEASEAnnals Of The Rheumatic Diseases, 2019
- Interferon-γ: an overview of signals, mechanisms and functionsJournal of Leukocyte Biology, 2003
- Interferon-induced nuclear signalling by Jak protein tyrosine kinasesNature, 1993